Some current treatments for T2DM have already been
tested concerning their possible effects in reducing glucose
variability as well as reducing glycated hemoglobin
(HbA1c) [8]. Exercise, which is one of the cornerstones
of treatment for hyperglycemia in T2DM because of its
beneficial effect on HbA1c [9], was recently shown to
reduce glucose variability in addition to its acute effects
on reducing glucose levels [7]. Vildagliptin and sitagliptin
are two drugs that were recently evaluated in a study
focusing on possible differences in daily glucose fluctuations
in patients with T2DM inadequately controlled
with metformin, and it showed that vildagliptin was